Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study Ankylosing spondylitis (AS) is a chronic, progressive inflammatory disease that primarily affects the axial skeleton, leading to inflammation of the sacroiliac joint, spine, and enthesess. Patient support program (PSP) services, such as nursing services, medication management and counseling, and co-pay assistance, have been shown to have a positive impact on medication adherence, and clinical and humanistic outcomes, and are also instrumental in reducing the healthcare utilization and costs associated with the management of AS. Hence, PSPs have been proposed to educate and empower patients in order to improve adherence, reduce cost, and improve both treatment satisfaction and outcomes by encouraging effective interaction between caregivers and patients. Courtesy of IQVIA Canada.